63631-09-4

Basic information

• Product Name: 2-CYANO-N-(2-METHOXY-PHENYL)-ACETAMIDE
• Synonyms: 2-cyano-N-(2-methoxyphenyl)ethanamide
• CAS NO: 63631-09-4
• Molecular Formula: C₁₀H₁₀N₂O₂
• Molecular Weight: 190.2
• Mol File: 63631-09-4.mol

Chemical Properties

• Melting Point: 163-165 °C
• Boiling Point: 392°Cat760mmHg
• Flash Point: 190.9°C
• Appearance: /
• Density: 1.216g/cm³
• Vapor Pressure: 2.36E-06mmHg at 25°C
• Refractive Index: 1.575
• PKA: -0.97±0.10(Predicted)
• CAS DataBase Reference: 2-CYANO-N-(2-METHOXY-PHENYL)-ACETAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-CYANO-N-(2-METHOXY-PHENYL)-ACETAMIDE(63631-09-4)
• EPA Substance Registry System: 2-CYANO-N-(2-METHOXY-PHENYL)-ACETAMIDE(63631-09-4)

Safety Data

• Hazardous Substances Data: 63631-09-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
2-CYANO-N-(2-METHOXY-PHENYL)-ACETAMIDE is used as a research compound for its potential biological activities, particularly in the development of new drugs targeting various diseases.
Used in Antimicrobial Applications:
In the field of antimicrobial research, 2-CYANO-N-(2-METHOXY-PHENYL)-ACETAMIDE is used as an active ingredient to combat microbial infections due to its antimicrobial properties.
Used in Anticancer Applications:
2-CYANO-N-(2-METHOXY-PHENYL)-ACETAMIDE is used as a potential anticancer agent, as it has shown promise in inhibiting the growth of cancer cells and may be further developed into a therapeutic agent for cancer treatment.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-CYANO-N-(2-METHOXY-PHENYL)-ACETAMIDE is used as a starting material or intermediate in the synthesis of more complex molecules with therapeutic potential. Its unique structure and functional groups make it a valuable component in the design and development of new pharmaceuticals.

InChI:InChI=1/C10H10N2O2/c1-14-9-5-3-2-4-8(9)12-10(13)6-7-11/h2-5H,6H2,1H3,(H,12,13)

Upstream product

• 90-04-0 2-methoxy-phenylamine 
• 105-56-6 ethyl 2-cyanoacetate 
• 36140-83-7 1-cyanoacetyl-3,5-dimethylpyrazole 
• 372-09-8 cyanoacetic acid 

Downstream Products

• 1042166-59-5 C₂₅H₁₉N₃O₂ 
• 1042166-58-4 C₂₀H₁₇N₃O₃ 
• 1092546-81-0 5-(4-chlorophenyl)-2-cyano-N-(2-methoxyphenyl)-5-oxo-3-(trifluoromethyl)pentanamide 
• 1254945-00-0 ethyl 5-cyano-2-hydroxy-1-(2-methoxyphenyl)-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 1254944-96-1 2-amino-5-cyano-N,1-di-(2-methoxyphenyl)-6-oxo-1,6-dihydropyridine-3-carboxamide 
• 1254945-01-1 2,4-dicyano-N₁,N₅-di-(2-methoxyphenyl)pent-2-enediamide 
• 1315553-26-4 2-amino-4-methylthio-6-oxo-1-(2-methoxyphenyl)-N-(p-fluorophenyl)-5-cyano-1,6-dihydropyridine-3-carboxamide 
• 1315553-27-5 2-amino-4-methylthio-6-oxo-N-(2-methoxyphenyl)-1-(p-fluorophenyl)-5-cyano-1,6-dihydropyridine-3-carboxamide 
• 1315553-18-4 2-amino-4-methylthio-N-(2-methoxyphenyl)-6-oxo-1-phenyl-5-cyano-1,6-dihydropyridine-3-carboxamide 
• 1315553-19-5 2-amino-4-methylthio-1-(2-methoxyphenyl)-6-oxo-N-phenyl-5-cyano-1,6-dihydropyridine-3-carboxamide 
• 735321-27-4 3-amino-3-(hydroxyimino)-N-[2-(methoxy)phenyl]propanamide 
• 328540-70-1 C₁₇H₂₀N₂O₂S 
• 89733-17-5 2-Cyano-2-cyclohexylidene-N-(2-methoxy-phenyl)-acetamide 

Relevant articles and documents

Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma

Development of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors is of great value and significance in the treatment of neoplastic disorders and inflammatory and autoimmune diseases. However, there is a lack of effective MALT1 inhibitors in clinic. Herein, a novel class of potent 5-oxo-1-thioxo-4,5-dihydro-1H-thiazolo[3,4-a]quinazoline-based MALT1 inhibitors and their covalent derivatives were first identified and designed through high-throughput screening. We demonstrated that compounds 15c, 15e, and 20c effectively inhibited the MALT1 protease and displayed selective cytotoxicity to activated B cell-like diffuse large B cell lymphoma with low single-digit micromolar potency. Furthermore, compound 20c specifically repressed NF-κB signaling and induced cell apoptosis in MALT1-dependent TMD8 cells in a dose-dependent manner. More importantly, 20c showed good pharmacokinetic properties and antitumor efficacy with no significant toxicity in the TMD8 xenograft tumor model. Collectively, this study provides valuable lead compounds of MALT1 inhibitors for further structural optimization and antitumor mechanism study.

Structure-based design, synthesis and biological evaluation of a newer series of pyrazolo[1,5-a]pyrimidine analogues as potential anti-tubercular agents

In-depth study of structure-based drug designing can provide vital leads for the development of novel, clinically active molecules. In this present study, twenty six novel pyrazolo[1,5-a]pyrimidine analogues (6a-6z) were designed using molecular docking studies. The designed molecules were synthesized in good yields. Structural elucidation of the synthesized molecules was carried out using IR, MS, 1H NMR and 13C NMR spectroscopy. All the synthesized compounds were evaluated for their in-vitro anti-tubercular activity against H37Rv strain by Alamar Blue assay method. Most of the synthesized compounds displayed potent anti-tubercular activities. Amongst all the tested compounds 6p, 6g, 6n and 6h exhibited promising anti-tubercular activity. Further, these potent compounds were gauged for MDR-TB, XDR-TB and cytotoxic study. None of these compounds exhibited potent cytotoxicity. Stability of protein ligand complex was further evaluated by molecular dynamics simulation for 10 ns. All these results indicate that the synthesized compounds could be potential leads for further development of new potent anti-tubercular agents.

From cycloheptathiophene-3-carboxamide to oxazinone-based derivatives as allosteric HIV-1 ribonuclease H inhibitors

The paper focussed on a step-by-step structural modification of a cycloheptathiophene-3-carboxamide derivative recently identified by us as reverse transcriptase (RT)-associated ribonuclease H (RNase H) inhibitor. In particular, its conversion to a 2-aryl-cycloheptathienoozaxinone derivative and the successive thorough exploration of both 2-aromatic and cycloheptathieno moieties led to identify oxazinone-based compounds as new anti-RNase H chemotypes. The presence of the catechol moiety at the C-2 position of the scaffold emerged as critical to achieve potent anti-RNase H activity, which also encompassed anti-RNA dependent DNA polymerase (RDDP) activity for the tricyclic derivatives. Benzothienooxazinone derivative 22 resulted the most potent dual inhibitor exhibiting IC50s of 0.53 and 2.90 μM against the RNase H and RDDP functions. Mutagenesis and docking studies suggested that compound 22 binds two allosteric pockets within the RT, one located between the RNase H active site and the primer grip region and the other close to the DNA polymerase catalytic centre.

Exploring the cycloheptathiophene-3-carboxamide scaffold to disrupt the interactions of the influenza polymerase subunits and obtain potent anti-influenza activity

With the aim to identify small molecules able to disrupt PA-PB1 subunits interaction of influenza virus (flu) RNA-dependent RNA polymerase, and based on previous structural and computational information, in this paper we have designed and synthesized a new series of cycloheptathiophene-3-carboxamide (cHTC) derivatives. Their biological evaluation led to highlight important structural insights along with new interesting compounds, such as the 2-hydroxybenzamido derivatives 29, 31, and 32, and the 4-aminophenyl derivative 54, which inhibited viral growth in the low micromolar range (EC50 = 0.18–1.2 μM) at no toxic concentrations (CC50 > 250 μM). This study permitted to obtain among the most potent anti-flu compounds within the PA-PB1 interaction inhibitors, confirming the cHTC scaffold as particularly suitable to achieve innovative anti-flu agents.

Low molecular weight amidoximes that act as potent inhibitors of lysine-specific demethylase 1

The recently discovered enzyme lysine-specific demethylase 1 (LSD1) plays an important role in the epigenetic control of gene expression, and aberrant gene silencing secondary to LSD1 dysregulation is thought to contribute to the development of cancer. We reported that (bis)guanidines, (bis)biguanides, and their urea- and thiourea isosteres are potent inhibitors of LSD1 and induce the re-expression of aberrantly silenced tumor suppressor genes in tumor cells in vitro. We now report a series of small molecule amidoximes that are moderate inhibitors of recombinant LSD1 but that produce dramatic changes in methylation at the histone 3 lysine 4 (H3K4) chromatin mark, a specific target of LSD1, in Calu-6 lung carcinoma cells. In addition, these analogues increase cellular levels of secreted frizzle-related protein (SFRP) 2, H-cadherin (HCAD), and the transcription factor GATA4. These compounds represent leads for an important new series of drug-like epigenetic modulators with the potential for use as antitumor agents.